Combination of Vaccine With IL‐12‐Armed Oncolytic Virus SKV‐012 Synergistically Potentiates Immune Responses in HPV‐Associated Malignancies
MedComm · 2026-04 · 7 (4)
DOI: 10.1002/mco2.70737 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 13.04.2026. Verfasst von Nian Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center Research Unit of Gene and Immunotherapy Chinese Academy of Medical Sciences Collaborative Innova…. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Currently, patients with advanced‐stage or refractory human papillomavirus (HPV)‐associated malignancies have few therapeutic options. Despite therapeutic HPV vaccines having been investigated, the lack of appreciable efficacy highlights the urgent need to develop more effective strategies. Here, we developed an immuno‐oncotherapy for HPV‐induced tumors based on an adenoviral (Ad)‐vectored therapeutic vaccine that contains concatemeric T cell epitopes, and evaluated oncolytic viruses (OV) as potential approach to enhance vaccine efficacy. We observed that the therapeutic vaccine encoding the HPV E7 oncoprotein epitope (Ad‐E7P) significantly inhibited tumor growth in HPV‐induced murine models by inducing systemic antitumor CD8+T cell responses and promoting the formation of tertiary lymphoid structures in peritumoral regions. We then evaluated the potential of combining the vaccine with an interleukin‐12 (IL‐12)–armed oncolytic herpesvirus (SKV‐012) in preclinical models. The combination therapy elicited potent antitumor responses by inducing antigen‐specific T‐cell expansion, remodeling the tumor microenvironment, and generating immune memory, which led to tumor clearance. Overall, these findings support that the vaccine synergizes with the OV as an effective approach to enhance antitumor immunity in HPV‐associated malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center Research Unit of Gene and Immunotherapy Chinese Academy of Medical Sciences Collaborative Innovation Center of Biotherapy West China Hospital Sichuan University Cheng…
- Department of Otolaryngology- Head & Neck Surgery West China Hospital Sichuan University Chengdu Sichuan China.
- Department of Biotherapy Cancer Center West China Hospital Sichuan University Chengdu Sichuan China.
- Department of Ophthalmology West China Hospital Sichuan University West China Medical School Chengdu Sichuan China.
- Frontiers Medical Center Tianfu Jincheng Laboratory Chengdu Sichuan China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Yang, N., Xu, L., Zheng, M., Lu, H., Chen, Y., Zhu, Z., Zeng, W., Wang, Z., Li, H., Li, J., Jiang, Z., Zeng, P., Wang, G., Xie, H., Zhang, Z., Yang, H., & Tong, A. (2026). Combination of Vaccine With IL‐12‐Armed Oncolytic Virus SKV‐012 Synergistically Potentiates Immune Responses in HPV‐Associated Malignancies. MedComm, 7(4). https://doi.org/10.1002/mco2.70737
Vancouver
Yang N, Xu L, Zheng M, Lu H, Chen Y, Zhu Z, et al. Combination of Vaccine With IL‐12‐Armed Oncolytic Virus SKV‐012 Synergistically Potentiates Immune Responses in HPV‐Associated Malignancies. MedComm. 2026;7(4). doi:10.1002/mco2.70737
BibTeX
@article{Yang2026,
author = {Yang, Nian and Xu, Long and Zheng, Meijun and Lu, Huaqing and Chen, Yongdong and Zhu, Zhixiong and Zeng, Wanqin and Wang, Zeng and Li, Hexian and Li, Jia and Jiang, Zheng and Zeng, Pingfu and Wang, Guoqing and Xie, Hai and Zhang, Zongliang and Yang, Hui and Tong, Aiping},
title = {Combination of Vaccine With IL‐12‐Armed Oncolytic Virus SKV‐012 Synergistically Potentiates Immune Responses in HPV‐Associated Malignancies},
journal = {MedComm},
year = {2026},
volume = {7},
number = {4},
doi = {10.1002/mco2.70737}
}
EUVIMED